As you embark on your job search, prepare for an interview or conduct competitive intelligence during your career, you may find yourself searching for information about a company or industry. While a company’s website is the natural place to start your search, there are other resources that you can use to find this type of information.
I have divided the resources below into those that are best for company information and those that are best for industry information. However, several resources, including ABI/Inform Collection, D&B Global Business Browser, Nexis Uni and Factiva, provide both types of information.
Many business databases utilize industry classification codes, which group similar products and services, to organize information. Using these codes in your search can help you find information about a particular industry. The standard industry classification code system in the United States is the North American Industry Classification System (NAICS), which replaced the Standard Industrial Classification (SIC) system. Some business databases still SIC, although it is no longer updated. The NAICS code sector most likely to be of interest to you is 32541, Pharmaceutical and medicine manufacturing.
ABI/Inform Collection: Business literature database. Indexes journals, case studies, working papers, reports, newspapers and trade magazines. Use search fields to restrict search to company or publication title. Full text available for most documents. Requires Tufts username and password to access.
D&B Global Business Browser: Detailed company profiles, news and industry reports, compiled by Dun & Bradstreet. Search by company name or build a list of companies based on the criteria of your choice, such as location, industry or size. Requires Tufts username and password to access.
Massachusetts Biotechnology Council (MassBio): Nonprofit organization that provides services and support for more than 1,000 Massachusetts-area biomedical companies, academic institutions and organizations. To discover local companies, search the membership directory by category and subcategory. The Career Center offers job search advice and job postings. Free public access.
Nexis Uni: Formerly LexisNexis Academic, this database provides news, business and legal information from journals, newspapers, television broadcasts and legal proceedings. To find company profiles, click the ‘Company Info’ button on the homepage. Requires Tufts username and password to access.
ReferenceUSA: Directory of more than 15 million public and private companies in the United States. Particularly useful for finding information on smaller companies. Search by company name, business type, location, or even executive gender or ethnicity. Requires Tufts username and password to access.
Biotechnology Innovation Organization (BIO): Representative organization for biotechnology companies, academic institutions and associations in the United States and around the world. Resources available on the BIO website include industry analysis reports, a blog and SmartBrief, a daily newsletter that provides summaries of news from the biotech industry. Free public access.
Factiva: From the Dow Jones Company, this global news database provides the full text of thousands of newspapers and trade magazines. Also searches select websites and blogs. Search by company or industry. Alternatively, click the ‘Companies/Markets’ tab in the menu bar to view company and industry snapshots. Requires Tufts username and password to access.
Harvard Business School Working Knowledge: Harvard Business School newsletter with articles, case studies, op-eds, classroom lessons and working paper summaries that connect “leading edge research and ideas on business management with practitioners, thought-leaders and academics”. Browse by topic, industry, geography or publication-type category. Free public access.
McKinsey & Company Insights: Articles, interviews, videos and commentaries on the pharmaceutical and medical products industry, from the consulting firm McKinsey & Company. Free public access.
TBBC, in collaboration with the Office of Alumni Relations will be hosting a speed networking night! Meet fellow students and Tufts alumni who are working in the biomedical field from across all of Tufts campuses and programs, including Sackler, Fletcher, Medical, Dental, Nutrition, and the Gordon Institute. Mingle with old friends and new. We look forward to seeing you! Food and drinks will be served at this facilitated networking event.
TBBC Biotech BUZZ with Lily Ting: F Apr 14 — 9AM, M&V Lobby (Stearns 108)
Dr. Lily Ting is a life scientist and entrepreneur with 12 years of experience in academia and industry. Lily received her PhD from New South Wales University in Sydney and a post doc in the Gygi Lab at Harvard Medical School. After her experience leading projects in the academic sphere, Lily worked in a business development role at Athletigen and is now an Associate at PureTech Health. PureTech is a venture creation firm focused on bringing innovative solutions to the fields of neuroscience, immunology, and gastrointestinal diseases. She is also an avid dragon boat racer and just won gold, silver, and bronze in Puerto Rico!
Representatives from ClearView Healthcare Partners will speak to students about consulting and ClearView’s Connect to ClearView program for advanced degree candidates.
TBBC, the Sackler Dean’s Office, GSC “Sackler Speaks” Flash Talk Competition: M Apr 24 — 5PM, Sackler 114
A well-developed flash talk is an effective tool to quickly and easily communicate your work to others. These take time to develop and usually evolve over a series of iterations. Sackler students will have a chance to give their scientific flash talks before a judging panel and other students. All presenters will receive helpful feedback and compete for nice prizes. This will be a low-key, fun event with appetizers and beer, and a chance to network with other students and professionals.
TBBC Biotech Buzz with Joel Batson, PhD, of RA Capital
F Feb 24: TBBC hosted Joel Batson, Science Project Manager at RA Capital. Joel introduced students to a new web-based tool he is developing and offered students the opportunity to collaborate with him and his team.
TBBC Career Seminar: Teresa Broering, Director of R&D, Affinivax
Tu Apr 4: Teresa Broering, current Director of R&D at Affinivax, a Cambridage, MA-based company developing a next generation approach in vaccine technologies, and former Director of Immunology at AbVitro as well as Senior Director of Product Discovery at MassBiologics, joined us for a discussion of her career path and her current role with Affinivax, and the current state of the biotech industry.
TBQA-oSTEM Joint Networking Mixer and Panel
We are having our TBQA-oSTEM Joint Networking Mixer and Panel on Friday, 11/18 from 6:00-8:00pm in the Crane Room on the Medford Campus. Food will be provided!
TBQA Transgender Health Panel: December 1, 3pm, Sackler Auditorium
The Tufts Biomedical Queer Alliance (TBQA) invites you to come learn about the current state of transgender healthcare. We are pleased to welcome Dr. Anne Koch, DMD, to share her personal experiences of the healthcare system as both a patient and provider. A professional panel composed of Dr. Julie Thompson (Primary Care, Fenway Health); Dr. Stephanie Roberts (Endocrinology, Boston Children’s Hospital); and Cei Lambert (Trans Patient Advocate, Fenway Health) will join Dr. Koch in a panel discussion of the services they provide from both medical and social perspectives. A complimentary reception will follow.
TBBC Case Study Group – Mondays — 5-7PM, Jaharis 508
Practice solving cases, gain insight and tips, and learn more about the field of consulting.
TBBC Tufts Biomedical Data Science Club: Information Session – Tu Nov 29 — Time and location TBA
The Tufts Biomedical Data Science Club is a resource for students wishing to learn and apply programming techniques in order to tackle big data problems in the biomedical sciences. No programming experience required! The club hosts bi-monthly meetings, works on group projects, and provides opportunities to hear invited speakers and network with others interested in big data. Please email Matt Kelley at email@example.com with any questions.
TBBC Seminar Series: Liz O’Day, Founder and CEO of Claris Therapeutics – Tu Dec 6 — 5:30PM, Sackler 216A
Olaris is a venture-backed drug discovery company that uses a proprietary NMR-metabolite profiling platform to unlock aspects of human metabolism that could never before be analyzed. Focusing on diseases with limited to no treatment options, Olaris uses their technology to uncover previously unknown biomarkers and molecular targets to develop breakthrough therapies that fundamentally alter how these diseases are diagnosed and treated.
TBBC Consulting Seminar Series: Peter Bak, PhD – Tu Dec 13 — 5:30-7:30 PM, Sackler 221
Join us for a discussion with Peter Bak, Manager at Back Bay Life Science Advisors. Dr. Bak will talk about transitioning from a PhD program to life sciences consulting and career opportunities at BBLSA.
TBBC Health Advances presents, “Diagnostics Commercialization Challenges”
Th Oct 6: TBBC hosted Sackler alum and Partner at Health Advances, Dr. Donna Hochberg (SK03), who discussed the career path that led her from the bench to her current role as the leader of the firm’s Diagnostics and Life Science Tools Practice. She also led the group through a business case study exploring the challenges of bringing diagnostics to market.
TBBC Biotech Buzz with Hannah Mamuszka
F Oct 21: Hannah Mamuszka, picked by Future of Biopharma as one of 5 women to watch in Boston, and founder and CEO of Alva10, a company specializing in precision medicine, joined us for an informal conversation about the future of diagnostics, the latest news in biotech, her career, and Alva10.
TBBC, GSC, and the Sackler Dean’s Office Career Exploration Panel
Th Nov 3: A panel of senior graduate students provided insight about steps that newer students can take to prepare themselves for a variety of career paths, including: academic/industry science, teaching, entrepreneurship, science communication, policy, data science, venture capital, and consulting. (For a more in-depth recap, read the Insight article here!)
Tufts Mentoring Circles (TMC)
from Daniel WongCMP
This year, the graduate student and post-doc mentoring circle programs have merged together to form a larger, single Tufts Mentoring Circles program that started for the 2016-2017 academic year with a kick-off event on Thursday, October 6. In total, 71 people are participating in the Mentoring Circles program this year: 24 mentors, 21 graduate students, and 26 post-docs between the Boston and Medford campuses. These mentors, who are faculty, post-docs, senior graduate students, and industry and non-traditional professionals working in different fields, will be working in pairs to advise and facilitate discussions with small groups of post-doc and graduate student mentees over the course of this year. Mentors and mentees were matched together based on their personal and professional development interests indicated in the registration survey that was available online in September. Each group, or circle, will meet monthly on their own schedules to have discussions as they see fit on topics they choose. A closing event will be held toward the end of the academic year, likely in May or June 2017. Registration is now closed for the year, but for more information and to be notified when registration opens next year, contact us at firstname.lastname@example.org.
The graduate student-focused Tufts Mentoring Circles program was founded in November 2014 through the Sackler GSC as a peer mentoring program to serve the professional and personal development needs of graduate students, and also facilitate inter-program and -department communication and collaboration. Tufts Mentoring Circles is based on the Association for Women in Science (AWIS) Mentoring Circles program.
April 2016: The excitement is palpable as the three co-founders sat around the table and planned out their first session as part of the inaugural Tufts Advisory Partners (TAP), a pro bono consulting group made up of Boston-area graduate students and postdocs. Alexandra Taracanova, Michaela Tolman, and Ji-Yong Kang were meeting to plan out their first engagement, or client relationship. They had selected a team of consultants, and now it was time to get to work. Tufts was about to be put on the map as an institution with high interests and talents for consulting and business development.
TAP was largely inspired by the sudden explosion in interest for the Case Study Group at Tufts. Students at Tufts, as well as institutions in the area, were becoming aware that career choice options were growing, make it an ideal time for TAP to emerge. Realizing the unmet need for hands-on opportunities in life sciences consulting, the founders of TAP got together in January 2016 and came up with a solution. TAP provides strategy services to biotechnology companies to develop their business. In working with a potential client, TAP will consult on how to set up the business, help them expand, or provide market research and due diligence. What makes this new consulting group unique is the ability to build an organization from the ground up, recruit clients, make their own rules, and pick projects to work on–in other words, they are essentially a fully functioning, autonomous firm that will provide a real product that will impact the biotechnology market. However, another integral goal in creating TAP was to connect enthusiastic and committed grad students and postdocs with the opportunity to use their talents.
For their first engagement, TAP selected a mid-sized medical devices company from several options. They planned to spend six weeks on the engagement, working with two teams. Of the three partners, Ms. Taracanova would work primarily with the client, and Ms. Tolman and Ms. Kang would each lead one of the teams as an engagement manager. Before the engagement began, and even before they could release the identity of the client, the eagerness and enthusiasm from the TAP partners was obvious. In particular, Ms. Taracanova was excited by the prospect of teamwork in the engagement teams and “seeing the two teams work together and move forward to deliver the end product.”
The team members for this first engagement hailed from three institutions: Tufts University, Boston University, and Harvard University. Throughout the engagement, team members collected information from key opinion leaders, analyzed the data, and presented recommendations on business strategy for the company. Both teams worked to develop market entry strategies for one of the company’s assets. As the members were from different institutions and departments, there was ample opportunity to network and get to know other students and postdocs who were interested in the consulting field. However, after completion of the engagement, it was clear that the team members first and foremost gained a valuable and rewarding experience. Christina Hao, a team member from Boston University, said of her experience: “I worked with TAP for six intense weeks on a consulting project, where I was able to gain hands on experience with solving business problems in a hypothesis-driven, structured manner, as well as honing my presentation and leadership skills. The level of teamwork was incredible, and the engagement manager was very professional and genuinely cared about our learning goals. TAP is hands down the most enriching, rigorous and fulfilling business experience I have experienced so far as a graduate student.” What was perhaps key to the consultants who participated in this engagement was the learning experience, and Michael Pereira, from Tufts University, reports that “as a first-time consultant, TAP exceeded all of my expectations. I learned more about the consulting profession in those six weeks than any number of books or classes could possibly teach me. It is an absolute must for anyone seeking a career in life sciences consulting!”
The team members were not the only people who had positive reviews for the first TAP engagement; the client, now revealed to be SteadMed Medical, also had encouraging comments. The CEO disclosed that “[he] was very pleased with the personal engagement and passion the entire team embraced throughout the project. The final report was clear, concise and supported with facts and data. [They were] excited to execute on the recommendations made.” The marketing manager of the company describes the TAP engagement with the following: “The quick uptake of our industry, its challenges, and our visions were outstanding. From the first week, we felt there was a deep understanding of how to take our questions and deliver them back with tangible perceptions and directions for us to move forward. At the next given opportunity, we will engage with TAP again to leverage their passion, knowledge, and ability to deliver promising direction with a message tailored to a market we thought only we knew so well.”
With the first engagement behind them and with success, no less, the TAP team is looking forward. They are looking to begin a second engagement in August, and to build upon this first experience to improve, further engage, and delve deeper. With the growing interest in life science consulting, they should have no problem recruiting more team members who are interested in venture capital, life science investing, and the life science business in general. And if the initial reviews are any hint to the future, the next client they select from their list of options will benefit enormously as well.
Applications for TAP’s second engagement open August 1st, 2016. If you are interested in applying or have a business that would benefit from TAP’s services, please contact email@example.com.
In an effort to continually explore the interface between science and business, Tufts Biomedical Business Club recently caught up with Dr. Zach Scheiner, an Associate at RA Capital Management, for a discussion about his experience in the healthcare investment industry.
RA Capital Management is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies. Prior to his current role at RA Capital, Zach worked as a Science Officer at the California Institute for Regenerative Medicine, where he managed a portfolio of research programs concentrated in translational neuroscience. He holds a BS in Molecular Biophysics and Biochemistry from Yale University, and a PhD in Neurobiology and Behavior from the University of Washington.
As an Associate for RA Capital, Zach’s efforts are realized through the team’s core research division, TechAtlas. This division is a scientifically trained team that maps out competitive landscapes in a continual effort to survey the landscape and identify emerging therapeutics and technologies that will reshape how physicians treat disease. The interview is edited for brevity and clarity.
Tell me about the career path that led you to your job. How did you become involved with RA Capital Management?
My interest in biomedical science and research began as an undergrad, when I had several summer research internships and was exposed to a few different fields of research. At the same time I had my first opportunity to teach science classes at a local high school and quickly realized that I also had a passion for teaching. After graduating, I decided to teach middle school science and math for a year (which turned into three) before returning to research and going to grad school.
I attended the Neurobiology & Behavior graduate program at The University of Washington in Seattle. My thesis work focused on the molecular basis of memory and drug addiction. Though I enjoyed my time as a graduate student, by my fourth year I began to realize that the academic career path and spending more years at the lab bench were not for me. I really enjoyed reading primary literature, planning experiments, and reviewing/analyzing data, so as I finished up graduate school I began looking at alternatives where I might be able to incorporate these interests as well as leverage my scientific background in a non-research capacity.
I found a great opportunity at the California Institute for Regenerative Medicine (CIRM) in San Francisco. CIRM funds stem cell research at institutions throughout California with the goal of advancing promising stem cell based therapies into clinical trials and ultimately to patients. I began as a science writer and quickly moved to a position managing a portfolio of translational research programs. In this position, I worked closely with funded scientists to help set milestones and success criteria, assess progress, and, however possible, facilitate success. In my six years at CIRM I learned a tremendous amount about the drug development process, gained experience reviewing and analyzing data, and developed management skills, all of which have been invaluable in my current role at RA Capital.
My move to RA Capital was the result of my wife being offered an assistant professorship at Brown University. In preparation for the move from one coast to the other I reached out to everyone in my network, including an old lab-mate I had stayed in touch with from graduate school who was now an Associate for RA Capital. I had a long-time interest in biotech investing, nurtured by my dad, and had been learning about this part of the industry in my spare time. Luckily, RA was hiring and the rest is history. For me, RA Capital was a perfect fit. I can put my communication and analytical skills from teaching, grad school and CIRM to good use and I love staying immersed in cutting-edge science while learning more about the investment side of the biotech industry.
What are the duties/functions/responsibilities of your job?
As an Associate with RA Capital, my primary role involves creating dendrograms (mind-maps) of specific diseases or capabilities within the healthcare industry. These comprehensive landscape maps take all the available drugs, both on the market and still in development, and put them into the context of current standard of care and unmet needs. They help our team fully appreciate and contextualize the market potential of assets and companies before making investments. Mapping out a disease landscape is a research-intensive process that involves surveying the literature, meeting with companies with assets in the space, speaking directly to physicians, attending scientific conferences, and analyzing data. The process can take several months to complete but the maps are never truly finished. Therapeutic landscapes are constantly evolving, new data are released and new licensing and acquisition deals are made. Our maps are equally dynamic and a lot of my time is spent staying up to date with the latest news and data coming out in the areas I cover.
In addition to mapping, Associates also join the investment team in diligence projects on specific investment opportunities. Our maps are a great way of contextualizing drugs and their competitors and can help our team identify potential new opportunities but it’s always critical to dig deeper before making an investment. One of the most rewarding parts of my job is seeing all the work I’ve put in researching and understanding a therapeutic space pay off with insights that are potentially investable, or that directly benefit a diligence project.
On a day-to-day basis I also survey industry news and the scientific literature not only to keep up with the science but to search for new investment opportunities that could be licensable for an RA Capital portfolio company or even form the basis for a new company. I also enjoy being involved in the recruiting process at RA and playing a small role in shaping the future of the company.
What is the most rewarding part about your job?
Personally, the most rewarding part of my work is knowing that we are investing in companies that are developing therapies for patients that really need them! These companies often have no marketed drugs and need capital to advance their assets through clinical trials and into the hands of patients. When I think about the work that I do, I know I am helping to identify great science, underappreciated drugs, and promising new opportunities. And I hope that by influencing where RA Capital’s dollars are invested, I’m impacting the whole healthcare ecosystem in a positive way.
What experiences best prepared you for your job?
I think all of my previous work experiences helped prepare me for RA Capital, the first of which was teaching. Communication is such an essential skill and getting an opportunity to develop this early in my career has been a huge benefit. Having controlled a classroom every day for three years definitely makes communicating with colleagues, companies and scientific experts a little easier. Effective communication is a vital part of this job.
The second experience is my time spent as a graduate student. In graduate school I learned how to rigorously analyze data, both my own and from the literature. I developed my critical thinking and analytical skills and the ability to quickly identify key questions, design key experiments, and understand the limitations of a study.
Lastly, at CIRM I learned the process of moving a drug from the lab to the market and everything in between. I also regularly participated in grant review meetings with panels of scientists, clinicians, and patient advocates. These meetings gave me the opportunity to learn what was truly important to each group. While the views and opinions would often vary between the groups, one key takeaway was that for a drug to succeed, doctors have to want to prescribe it and patients have to want to use it. My experience at CIRM taught me to evaluate drugs with the patient perspective in mind; new therapies are worthless unless patients will use them, and sometimes improvements that appear marginal can be very meaningful to patients.
What skills or personal characteristics do you feel contribute most to success in this industry?
Very often, investment firms require that applicants have a background in finance, an MBA, or prior experience in the industry. That is not the case at RA Capital. I wouldn’t say any particular background or degree is required, but there are certainly skills that are critical. Analytical skills, for example. The ability to rigorously analyze data and quickly get to the “meat” of primary literature or a clinical data set is invaluable. Another key skill is effective writing and communication. Much of my day is spent writing and talking. I am continuously expressing my thoughts and providing analysis and it is important to do so concisely and effectively.
In terms of personal characteristics, I would highlight skepticism. Being skeptical is a common trait among scientists due to the nature of research, but this skill is especially important when meeting with companies. Every company is trying to convince us that their assets or data are the best. Skepticism is required to separate the pitch from the quality of the science.
Humility is another important personal characteristic. To put it simply, in something as complicated as drug development, it’s easy to be wrong! There are so many variables to consider, and science changes so quickly; it’s essential to have an open mind and be humble about everything you do not know.
What are the biggest challenges you face as an associate for RA Capital Management?
I think the largest challenge I face is simply the pace of the industry and science itself. There is new data coming out all the time; from company press releases, new primary literature, scientific conferences—the amount of information can be overwhelming. Developing the ability to quickly assimilate and analyze new information is the biggest challenge. But it’s also one of the things I enjoy most about my job. In this field you have to enjoy constant learning and also get good at processing information quickly enough to inform an investment decision. The fast pace is challenging but exciting.
What are some other opportunities within RA Capital Management for scientists aside from the TechAtlas Research Division?
Most opportunities for PhD trained scientists are within our TechAtlas research team. This team is made up primarily of PhD trained scientists in either Associate or Scientific Writer positions. The Science Writers work closely with the Associates as they build the story of their map, acting as a thought partner to develop the key insights for standard of care, unmet needs, and investable opportunities for each disease. As members of the research team gain experience, they can specialize in one of several areas, including early-stage assets, strategic analysis of licensing and partnerships, and equity analysis.
For somebody interested in pursuing this career, what would be your advice to best prepare them?
I would highly recommend that PhD candidates supplement their education in three areas: biostatistics, clinical trials, and FDA regulatory pathways. These topics are not always emphasized or even addressed in many graduate programs. A working knowledge of biostatistics goes a long way; being able to understand statistical pitfalls and the pros and cons of different analyses is invaluable. I would also recommend becoming familiar with clinical trials: the general FDA requirements for advancing drugs into Phase 1 trials and the typical development path for new therapies in your field of interest. Few graduate students get exposed to these areas. I would strongly suggest looking beyond the specific questions of own research project to get an understanding of the broader context: the standard of care for the disease, unmet needs, and competing approaches. If your research isn’t disease or therapy focused, choose a disease of interest or imagine potential applications of your work and research those. Putting new research and data into a broad context is a lot of what we do, so the earlier you can start practicing, the better prepared you will be.
The Tufts Biomedical Business Club (TBBC) is a student run organization whose mission is to cultivate business leaders in the health and life sciences. TBBC is a growing community of graduate, medical, dental and nutrition students, postdocs, physicians, scientists and alumni. It provides members with opportunities to learn about consulting, business development, entrepreneurship, intellectual property and more. We engage our members though a number of initiatives including a seminar series, Biotech Journal Club, Consulting Case Study Group, panel discussions, and most recently Biotech BUZZ. E-mail firstname.lastname@example.org for more information
TBBC Case Study Group
Mondays – 5-7PM, Jaharis 508
Julie Hewitt Coleman guides students and postdocs through the case interview process. Practice solving cases, gain insight and tips, and learn more about the field of consulting.
TBBC Dr. Dave Greenwald
Tu Feb 9 – 5-6:30PM, Sackler 114E
Dr. Dave Greenwald, a 2010 Sackler alum, now Director of Business Development and Corporate Sponsorships at Johns Hopkins Technology Ventures, will give a career seminar titled, “Starting a Company: Practical Advice for a Precarious Pursuit.”
TBBC Dr. Lauren Linton
Th Feb 25 – 5-6:30PM, Sackler 316
Dr. Lauren Linton, Deputy Director of the Tufts Institute for Innovation, formerly co-Director of the Sequencing Center at the Whitehead Institute and Associate Director of the Center for Genome Research at the Whitehead/MIT, will give a career seminar titled, “Don’t Be Afraid to Experiment.”
TBBC Biotech Journal Club
F Feb 26 — 12PM Noon, Jaharis 155
BJC will meet to discuss current topics in the biotech industry. To join the mailing list, email email@example.com with the subject line: BJC
TBBC Biotech Journal Club
F Jan 29: Townsend Benard gave a presentation on the Innovative Medicines Initiative, Europe’s largest public-private effort aimed at speeding the development of better and safer medicines for patients.
TBBC Sackler Speaks
Th Feb 4: TBBC partnered with the Graduate Student Council to host a flash talk competition among Tufts students. Eleven speakers gave 3-minute presentations on their research; Jess Davis-Knowlton took home first prize.
Shortly after returning from the holidays, the Career Paths Committee of the Sackler Graduate Council coordinated a biotech/startup mixer on January 6th, 2016 at the Field in Central Square. Representatives from bosWell, Neumitra, Genometry, Thrive Bioscience, as well as the COO of Editas Medicine donated their time to chat about their careers. The event was remarkably well attended by PhD students, as well as a handful of post-docs and MD/PhD students. Whether it was the draw of learning more about alternative career paths, or the casual venue, the event was an excellent success.